into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing Read more at the source #DrGPCR #GPCR #IndustryNews

well as target validation strategies for the discovery and development of novel therapeutic agents ranging Read more at the source #DrGPCR #GPCR #IndustryNews

Four of the biggest European networks on GPCR research (COST Actions Adher’n Rise and ERNEST plus DFG-funded We aim to connect renowned international experts of the field with early career ‘rising stars’. Read more at the source #DrGPCR #GPCR #IndustryNews

Read more at the source #DrGPCR #GPCR #IndustryNews

The Boston biotech revealed Wednesday afternoon that it would downsize its research to focus on its lead weeks after X4 pulled together a $55 million PIPE and amended a loan facility with Hercules Capital to reduce Read more at the source #DrGPCR #GPCR #IndustryNews

biotechnology company transforming the discovery of novel GPCR-targeted therapies (G-Protein Coupled Receptors ), today announced the promotion of Senior Vice President, Head of Research, Peter McNamara , PhD, to Chief Scientific Officer as well as the appointments of Barry Rubenstein as Senior Vice President, People Read more at the source #DrGPCR #GPCR #IndustryNews

#artificialintelligence #drugdesign #drugdiscovery" Read more at the source #DrGPCR #GPCR #IndustryNews

In 2007 he formed IndiPharm which was a full-service Contract Research Organization whose operational In 2016 the company was sold to Velocity fund partners and has been rebranded as InClinica . He received his undergraduate Bachelor of Science Degree in Pharmacy from The Philadelphia College of He went on to study medicine at the Royal College of Surgeons in Ireland before receiving his Medical #biotech #lifesciences #appointment #GPCR #Oncology" Read more at the source #DrGPCR #GPCR #IndustryNews

, a drug discovery and development company unlocking the therapeutic potential of G Protein-Coupled Receptors new data on Orion’s CCR2 antagonist, OB-004, demonstrating the ability of this powerful platform to rapidly Read more at the source #DrGPCR #GPCR #IndustryNews

June 2022 "G protein-coupled receptors (GPCRs) represent a major therapeutic target class as they play a key role in many (patho-) physiological processes. GPCRs respond to a wide variety of signals that range in size from photons to proteins (Foord et al., a challenge for the remainder." Read more at the source #DrGPCR #GPCR #IndustryNews

Michel Bouvier , Chief Executive Officer of IRIC, Principal Investigator of the Molecular Pharmacology Research The rank of Knight specifically rewards the implementation of an exemplary activity in a particular field Read more at the source #DrGPCR #GPCR #IndustryNews

immuno-oncology company and led the company through a successful IPO on Nasdaq in February 2021, and successfully raised Read more at the source #DrGPCR #GPCR #IndustryNews

City-based Kallyope , pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor (GPCR) targets with a goal of creating new drug discovery programs in the area of gastrointestinal diseases. " Read more at the source

biopharmaceutical company with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors Jon Wigginton will provide scientific expertise to support the company’s research and clinical development Read more at the source #DrGPCR #GPCR #IndustryNews

Read more at the source #DrGPCR #GPCR #IndustryNews

Read more at the source #DrGPCR #GPCR #IndustryNews

MacSweeney | Apr 20, 2022 Cliona MacSweeney, a project director in our Translational Medicine department, recently highly selective novel GPR52 agonist HTL00411718 to modulate centrally mediated locomotor activity in response to A2A receptor antagonists. potential for GPR52 agonists to control neuropsychiatric symptoms in conditions such as schizophrenia. " Read

drug discovery and development, announced today that it has moved a selective and potent M4 muscarinic receptor Read more at the source #DrGPCR #GPCR #IndustryNews

pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten follow-on Read more at the source #DrGPCR #GPCR #IndustryNews

Topline results from 40 subjects are expected in the second half of the calendar year." Read more at the source #DrGPCR #GPCR #IndustryNews

March 2022 " Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors Read more at the source #DrGPCR #GPCR #IndustryNews

pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of James Hassard as Read more at the source #DrGPCR #GPCR #IndustryNews

Are you ready? Tomorrow is the day for another Dr. GPCR Virtual Cafe. Bryan Roth There are 10 open tickets available. Get yours now!

Stay tuned as the episode will be released later this week. Subscribe today!

Subscribe to the podcast today and get notified when new episodes are released! You can also leave us a review on Apple Podcast!

Subscribe to the podcast today and get notified when new episodes are released!

#IPO #biotech #innovation #traitements #addiction #cannabis #Trisomie21 #Downsyndrome" Read more at the

of oliceridine injection compared to IV morphine, conducted in China by Nhwa Trevena is eligible to receive future success payments upon approval and commercialization milestones, as well as a 10% royalty on Food and Drug Administration (FDA) for use in adults for the management of acute pain severe enough to require Read more at the source #DrGPCR #GPCR #IndustryNews